Study guide

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation

Key Takeaways Explain This Topic AI

Abstracting follows a predictable order: confirm reportability, check the patient index for prior tumors, apply the multiple primary rules, gather source documents, code the items, write supporting text, then run edits.

Priority lists for conflicting documentation come from the standard setters: the Solid Tumor Rules for histology, the Grade Manual for grade, STORE for lymph node counts, and AJCC for staging time frames.

CoC's 2020 standards make abstracting timeliness part of each program's Standard 6.1 quality control plan, and STORE's Date Case Completed–CoC [2092] records when required items pass the "Hosp: CoC Required - All" edit set.

NAACCR text fields (for example Text--DX Proc--PE [2520], Text--DX Proc--Path [2570], Text--Staging [2600] and RX Text--Surgery [2610]) are required by NPCR and SEER; STORE notes that text is sent to state registries but not to the NCDB.

NAACCR says text must be entered manually from the medical record and must not be generated from coded values, because generated text cannot be used to check the codes.

Last updated: September 2026

The abstracting workflow

Case identification. Casefinding (Chapter 9) flags a possible case. Confirm that the tumor is reportable under STORE, SEER or NPCR, and state rules, and that it was diagnosed on or after the reference date.

Check the patient index. Search the registry for the patient. If the patient already has an accession number, this tumor gets the same accession number and the next sequence number (Section 11.1).

Decide the number of primaries. Apply the Solid Tumor Rules or the Hematopoietic and Lymphoid Neoplasm Coding Manual before coding anything else. A new primary gets a new abstract, and a recurrence is recorded in the follow-up items.

Assign Class of Case (Chapter 11). This controls which items CoC requires.

Gather source documents from every relevant setting: history and physical, imaging, endoscopy, laboratory, operative and pathology reports, consultations, treatment summaries, and outside records.

Code the items. These include demographics, diagnosis (site, histology, behavior, grade, laterality, Diagnostic Confirmation), staging (AJCC, Summary Stage 2018, SSDIs), first-course treatment, and follow-up.

Write the text. Document the evidence for each coded item in the NAACCR text fields.

Run edits. Correct the errors, apply override flags only when the unusual combination is verified, and let the software set the completion date.

Source documents and what they answer

Source Best for

History and physical; consultation notes Presenting symptoms, history, family and tobacco history, physical exam findings (for example, palpable nodes), treatment plan and intent

  • Imaging reports Clinical tumor size and extension, lymph nodes and metastases before treatment
  • Endoscopy reports Location (for example, distance from the anal verge), appearance and biopsy
  • Operative reports Gross extension, what was removed, residual disease, surgical approach

Pathology and cytology reports Histology and behavior, grade, size and extension, margins, lymph nodes, LVI, biomarkers

  • Laboratory reports Tumor markers and other values for SSDIs (PSA, CEA, LDH, AFP)
  • Radiation and systemic therapy records Modality, dose, fractions, agents, dates
  • Discharge summary A useful index to the stay; confirm details in the original reports
  • Official priority lists

When documents disagree, do not rely on a general "most authoritative document" idea. Use the priority list the standard setter publishes for the specific item:

Histology: each Solid Tumor Rules module gives a priority order for documentation . Tissue from the primary site comes first, and histology is coded from the diagnosis before neoadjuvant therapy. Code the more specific histology when the final diagnosis and the synoptic report differ.

Grade: the Grade Manual's priority is the synoptic report (CAP protocol), then the final diagnosis, then a physician statement.

Lymph node counts: STORE's priority is final diagnosis, then synoptic report, then microscopic description, then gross description.

Primary site: follow ICD-O-3 and the Solid Tumor Rules site instructions. Consult the physician advisor when the record does not identify a site.

Staging: AJCC rules define which information belongs to the clinical and the pathological time frames. For example, operative findings can support pathological T when the surgeon's resection meets AJCC criteria, and the pathology report does not automatically override every clinical fact.

Timeliness

CoC Standard 6.1 requires each program's quality control plan to evaluate abstracting timeliness every year, together with casefinding and the percentage of unknown values. The 2020 standards leave the specific timeliness target to the program's plan.

Date Case Completed–CoC [2092] is set automatically by the registry software once the items required for the case's Class of Case are abstracted and pass the " Hosp: CoC Required - All " edit set. It was created to measure abstracting timeliness and "may also be used as part of CoC Standard 6.1" timeliness monitoring. Follow-up information, delayed treatment and corrections may be added afterward.

RCRS (Standard 6.4) expects monthly submission of cases to the NCDB, so the registry must keep abstracting current throughout the year.

State central registries set their own reporting deadlines in law or rule. Many require facilities to report within about six months of diagnosis or first contact; check your state's rule.

Items required by Date Case Completed–CoC

  • Class of Case Items that must be complete
  • 00–22 Identification, demographic and diagnostic items
  • 10–22 Staging and hospital-specific treatment
  • 10, 12, 14, 20, 22 Summary treatment (treatment at any facility)
  • 00 NPI of the facility or physician the patient was referred to
  • 20–22 NPI of the referring facility or physician who diagnosed or treated the patient
  • NAACCR text fields
  • Item Text field Contents
  • 2520 Text--DX Proc--PE History and physical findings about this tumor
  • 2530 Text--DX Proc--X-ray/Scan Imaging results
  • 2540 Text--DX Proc--Scopes Endoscopic findings
  • 2550 Text--DX Proc--Lab Tests Lab and tumor marker results
  • 2560 Text--DX Proc--Op Operative findings
  • 2570 Text--DX Proc--Path Cytology and histopathology findings
  • 2580 / 2590 Text--Primary Site Title / Text--Histology Title Written description of site and histology
  • 2600 Text--Staging Staging information not entered elsewhere

2610–2670 RX Text--Surgery, Radiation (Beam), Radiation Other, Chemo, Hormone, BRM, Other First-course treatment details

  • 2680 Text--Remarks Overflow and supplemental information
  • 2690 Text--Place of Diagnosis Facility, physician office, city or state where the diagnosis was made
  • Rules for good text

Manual entry: NAACCR's rationale says text "must contain a description that has been entered by the reporter independently from the code(s)." Text that software generates from codes cannot be used to check those codes.

Justify the codes: each text item lists the coded items it should support. For example, RX Text--Surgery supports the surgery, lymph node surgery, margins and sequence items.

Include dates and sources: for example, "04/02/26 CT C/A/P: 3.1 cm R lower lobe mass, no adenopathy, no mets."

Use NAACCR-approved abbreviations , and do not repeat the same information in several fields.

Who uses it: NPCR and SEER list the text fields as required. Central registries use text to consolidate reports from several facilities and for quality control and special studies. STORE notes that text is not transmitted to the NCDB .

Worked example

A right hemicolectomy pathology report shows "adenocarcinoma, 5.2 cm, invades through the muscularis propria into pericolic fat, 0/18 nodes." The operative note mentions "dense adhesions to the retroperitoneum" but no invasion.

Text--DX Proc--Path: "03/14/26 R hemicolectomy: adenoca, mod diff, 5.2 cm, invades thru MP into pericolic fat; margins neg; LVI absent; 0/18 LN."

Text--DX Proc--Op: "03/14/26 open R hemicolectomy; dense adhesions to retroperitoneum, taken en bloc; no residual gross disease."

Coding: because adhesions are not tumor invasion, the pathological T comes from the pathology finding, pT3. That gives Regional Nodes Examined 18 and Positive 00.

Loading diagram... Abstracting workflow